| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033498 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(13 years from now) | |
| US11638697 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(13 years from now) | |
| US10143656 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(13 years from now) | |
| US11382864 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleansing a colon and methods of using same |
Aug, 2037
(13 years from now) | |
Sutab is owned by Braintree Labs.
Sutab contains Magnesium Sulfate; Potassium Chloride; Sodium Sulfate.
Sutab has a total of 4 drug patents out of which 0 drug patents have expired.
Sutab was authorised for market use on 10 November, 2020.
Sutab is available in tablet;oral dosage forms.
Sutab can be used as gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy.
The generics of Sutab are possible to be released after 04 August, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 10, 2023 |
Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient
Market Authorisation Date: 10 November, 2020
Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy
Dosage: TABLET;ORAL
SUTAB family patents
